Approval · Notice of Compliance 176 · 2004
PROGRAF: Notice of Compliance 176
Issued February 23, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 176
- Date
- February 23, 2004
- Company
- Fujisawa Canada Inc.Markham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for treatment of rheumatoid arthritis
- Therapeutic class
- Immunosuppressant
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PROGRAF | Not yet assigned | — |
Medicinal ingredients
- TACROLIMUS 0.5 MG per CAP
- TACROLIMUS 1 MG per CAP